Serum inflammatory factors such as MMP-9 are associated with post-percutaneous transluminal angioplastyacute myocardial infarction in coronary heart disease patients complicated by lower extremity arteriosclerosis obliterans.
Shao C, Wuren B, Chi G, Ren H, Li F, Song W, Wang B, Ding M.
Cell Mol Biol (Noisy-le-grand). 2023 Dec 31;69(15):38-43. doi: 10.14715/cmb/2023.69.15.6.
Coronary artery vasomotion after percutaneous transluminal coronary angioplasty.
Misra VK, Agirbasli M, Fischell TA.
Clin Cardiol. 1997 Nov;20(11):915-22. doi: 10.1002/clc.4960201104.
Ambulatory electrocardiography evaluation of the post-coronary artery bypass graft and post-percutaneous transluminal coronary angioplasty patient. Diagnostic and prognostic value.
Droste C, Roskamm H.
Cardiol Clin. 1992 Aug;10(3):431-48.
Diplopia After Coronary Revascularization.
Braga J, Neves F, Costa J, Meira D.
Acta Med Port. 2020 Oct 1;33(10):685-688. doi: 10.20344/amp.11751. Epub 2020 Oct 1.
FDG PET/CT in Dressler Syndrome.
Taywade S, Gupta T, Kumar R, Choudhary R, Kumar D.
Clin Nucl Med. 2023 Sep 1;48(9):e449-e451. doi: 10.1097/RLU.0000000000004754. Epub 2023 Jun 23.
Spontaneous regression of post-percutaneous transluminal coronary angioplasty aneurysm.
Abhyankar AD, Richmond DR, Bernstein L.
Int J Cardiol. 1997 Aug 8;60(3):233-8. doi: 10.1016/s0167-5273(97)00086-7.
Secondary prevention and learning needs post percutaneous coronary intervention (PCI): perspectives of both patients and nurses.
Kilonzo B, O'Connell R.
J Clin Nurs. 2011 Apr;20(7-8):1160-7. doi: 10.1111/j.1365-2702.2010.03601.x.
Comparative effectiveness and safety of prasugrel and ticagrelor in patients of acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty: A propensity score-matched analysis.
Ray A, Najmi A, Khandelwal G, Jhaj R, Sadasivam B.
Indian Heart J. 2024 Mar-Apr;76(2):133-135. doi: 10.1016/j.ihj.2024.03.001. Epub 2024 Mar 13.
Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. Multicenter European Research Trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
Hermans WR, Rensing BJ, Foley DP, Tijssen JG, Rutsch W, Emanuelsson H, Danchin N, Wijns W, Chappuis F, Serruys PW.
J Cardiovasc Pharmacol. 1993;22 Suppl 4:S45-57.
IL-1 cluster genes and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: a prospective, angiography-based evaluation.
Zee RY, Fernandez-Ortiz A, Macaya C, Pintor E, Fernandez-Cruz A, Lindpaintner K.
Atherosclerosis. 2003 Dec;171(2):259-64. doi: 10.1016/s0021-9150(03)00294-6.
